OEA for Young Adults With Alcohol Use Disorder
This study is looking at how a substance called oleoylethanolamide (OEA) might help young adults, aged 18 to 25, who have alcohol use disorder (AUD). Researchers want to see if OEA can reduce inflammation (swelling in the body), change the bacteria in your mouth (oral microbiome), improve thinking skills related to reward and impulsivity, and affect alcohol use. You would take 250 mg of OEA daily for 6 weeks. The study will compare OEA to a placebo (an inactive substance) to understand its effects. Success would mean seeing changes in inflammation markers like IL-6, TNF-α, and IL-1β after 6 weeks. The current status of this study is unclear.
- Study design
- This is an interventional study planning to enroll 42 participants. Researchers will compare OEA to a placebo.
- What's involved
- You would take 250 mg of OEA daily for 6 weeks. Your blood will be tested at the beginning and after 6 weeks to measure inflammation markers.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your progress will be checked at the beginning of the study and again after 6 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
OEA for Young Adults With Alcohol Use Disorder
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Change in Peripheral IL-6 ConcentrationBaseline and week 6
Blood-based concentration of interleukin-6 (IL-6) measured using immunoassay methods to assess systemic inflammation. Unit of Measure: pg/mL
- Change in Peripheral TNF-α ConcentrationBaseline and week 6
Blood-based concentration of tumor necrosis factor-alpha (TNF-α) measured using immunoassay methods to assess systemic inflammation.Unit of Measure: pg/mL
- Change in Peripheral IL-1β ConcentrationBaseline and week 6
Blood-based concentration of interleukin-1 beta (IL-1β) measured using immunoassay methods to assess systemic inflammation. Unit of Measure: pg/mL
- Change in Plasma Lipopolysaccharide (LPS) LevelsBaseline and week 6
Alpha diversity indices derived from sequencing of saliva samples to assess oral microbiome composition. Unit of Measure: pg/mL